Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 366

1.

Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1109-1133. doi: 10.6004/jnccn.2019.0043.

PMID:
31487687
2.

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.

Kurzrock R, Gurski LA, Carlson RW, Ettinger DS, Horwitz SM, Kumar SK, Million L, von Mehren M, Benson AB.

Ann Oncol. 2019 Oct 1;30(10):1647-1652. doi: 10.1093/annonc/mdz232.

3.

Failure to administer recommended chemotherapy: acceptable variation or cancer care quality blind spot?

Ellis RJ, Schlick CJR, Feinglass J, Mulcahy MF, Benson AB, Kircher SM, Yang TD, Odell DD, Bilimoria K, Merkow RP.

BMJ Qual Saf. 2019 Jul 31. pii: bmjqs-2019-009742. doi: 10.1136/bmjqs-2019-009742. [Epub ahead of print]

PMID:
31366576
4.

Comparison of Cancer Burden and Nonprofit Organization Funding Reveals Disparities in Funding Across Cancer Types.

Kamath SD, Kircher SM, Benson AB.

J Natl Compr Canc Netw. 2019 Jul 1;17(7):849-854. doi: 10.6004/jnccn.2018.7280.

PMID:
31319386
5.

Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape.

Obeng-Gyasi S, Kircher SM, Lipking KP, Keele BJ, Benson AB, Wagner LI, Carlos RC.

Cancer. 2019 Oct 15;125(20):3488-3493. doi: 10.1002/cncr.32360. Epub 2019 Jun 28. No abstract available.

PMID:
31251394
6.

Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205).

Gibson MK, Catalano P, Kleinberg LR, Staley CA 3rd, Montgomery EA, Jimeno A, Song WF, Mulcahy MF, Leichman LP, Benson AB 3rd.

Oncologist. 2019 Jun 21. pii: theoncologist.2018-0750. doi: 10.1634/theoncologist.2018-0750. [Epub ahead of print]

PMID:
31227647
7.

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.

Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB.

Oncologist. 2019 Nov;24(11):1446-1452. doi: 10.1634/theoncologist.2018-0921. Epub 2019 Jun 12.

8.

Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.

Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB 3rd.

Oncologist. 2019 Aug;24(8):1039-e642. doi: 10.1634/theoncologist.2019-0330. Epub 2019 May 28.

9.

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.

Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, Cloyd J, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Hammond LJ, Darlow SD.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):302-310. doi: 10.6004/jnccn.2019.0019.

PMID:
30959462
10.

Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models.

Pan L, Shang N, Shangguan J, Figini M, Xing W, Wang B, Sun C, Yang J, Zhang Y, Hu S, Ma Q, Wang J, Velichko Y, Yaghmai V, Benson AB 3rd, Zhang Z.

Am J Cancer Res. 2019 Mar 1;9(3):562-573. eCollection 2019.

11.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
12.

Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies.

Lentz R, Benson AB 3rd, Kircher S.

J Surg Oncol. 2019 Jul;120(1):85-92. doi: 10.1002/jso.25374. Epub 2019 Jan 16. Review.

PMID:
30650186
13.

Piloting a Financial Counseling Intervention for Patients With Cancer Receiving Chemotherapy.

Kircher SM, Yarber J, Rutsohn J, Guevara Y, Lyleroehr M, Alphs Jackson H, Walradt J, Desai B, Mulcahy M, Kalyan A, Benson AB, Agulnik M, Mohindra N, DeSouza J, Garcia SF.

J Oncol Pract. 2019 Mar;15(3):e202-e210. doi: 10.1200/JOP.18.00270. Epub 2019 Jan 9.

PMID:
30625023
14.

Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.

Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH.

Oncologist. 2019 Aug;24(8):1066-1075. doi: 10.1634/theoncologist.2018-0520. Epub 2019 Jan 4.

PMID:
30610008
15.

Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.

Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK.

Oncologist. 2019 Aug;24(8):1056-1065. doi: 10.1634/theoncologist.2018-0519. Epub 2019 Jan 3.

PMID:
30606883
16.

Pembrolizumab for the treatment of gastric cancer.

Kamath SD, Kalyan A, Benson AB 3rd.

Expert Rev Anticancer Ther. 2018 Dec;18(12):1177-1187. doi: 10.1080/14737140.2018.1526084. Epub 2018 Oct 3. Review.

PMID:
30280940
17.

From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.

Trosman JR, Weldon CB, Gradishar WJ, Benson AB 3rd, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA.

Value Health. 2018 Sep;21(9):1062-1068. doi: 10.1016/j.jval.2018.06.011. Epub 2018 Aug 3.

18.

Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, Munshi HG, Benson AB 3rd, O'Dwyer PJ.

JAMA Oncol. 2018 Dec 1;4(12):1707-1712. doi: 10.1001/jamaoncol.2018.3277.

19.

Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061.

PMID:
30006429
20.

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):852-871. doi: 10.6004/jnccn.2018.0060.

PMID:
30006428
21.

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. doi: 10.6004/jnccn.2018.0056.

PMID:
29891520
22.

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.

Chen EY, Blanke CD, Haller DG, Benson AB, Dragovich T, Lenz HJ, Robles C, Li H, Mori M, Mattek N, Sanborn RE, Lopez CD.

Am J Clin Oncol. 2018 Dec;41(12):1193-1198. doi: 10.1097/COC.0000000000000465.

23.

First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.

Broder MS, Cai B, Chang E, Yan T, Benson AB 3rd.

J Med Econ. 2018 Aug;21(8):821-826. doi: 10.1080/13696998.2018.1474748. Epub 2018 May 25.

PMID:
29741466
24.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.

PMID:
29632055
25.

Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers.

Reyngold M, Niland J, Ter Veer A, Bekaii-Saab T, Lai L, Meyer JE, Nurkin SJ, Schrag D, Skibber JM, Benson AB, Weiser MR, Crane CH, Goodman KA.

Adv Radiat Oncol. 2017 Oct 12;3(1):34-41. doi: 10.1016/j.adro.2017.10.001. eCollection 2018 Jan-Mar.

26.

Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis.

Broder MS, Cai B, Chang E, Neary MP, Papoyan E, Benson AB III.

Oncology. 2018;94(5):281-288. doi: 10.1159/000486282. Epub 2018 Mar 6.

PMID:
29510379
27.

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS.

J Clin Oncol. 2018 Apr 10;36(11):1112-1120. doi: 10.1200/JCO.2017.75.5413. Epub 2018 Feb 28.

28.

Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.

Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB 3rd.

Am Health Drug Benefits. 2017 Nov;10(8):408-415.

29.

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).

Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Catalano PJ, Kauh JS, Hall MJ, Saltzman JN, George TJ Jr, Zangmeister J, Chiorean EG, Cheema PS, O'Dwyer PJ, Benson AB 3rd.

Cancer. 2018 Feb 15;124(4):688-697. doi: 10.1002/cncr.30967. Epub 2017 Dec 6.

30.

Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.

Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, Hickey R, Kulik L, Ganger D, Flamm S, Atassi R, Atassi B, Sato K, Benson AB, Mulcahy MF, Abouchaleh N, Asadi AA, Desai K, Thornburg B, Vouche M, Habib A, Caicedo J, Miller FH, Yaghmai V, Kallini JR, Mouli S, Lewandowski RJ.

Hepatology. 2018 Oct;68(4):1429-1440. doi: 10.1002/hep.29691. Epub 2018 Jan 29.

PMID:
29194711
31.

An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).

Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson AB III, Blackstock AW.

Oncology. 2018;94(1):39-46. doi: 10.1159/000480295. Epub 2017 Oct 18.

32.

A Blueprint to Advance Colorectal Cancer Immunotherapies.

Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB.

Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16.

33.

Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis.

Benson AB III, Broder MS, Cai B, Chang E, Neary MP, Papoyan E.

World J Gastroenterol. 2017 Sep 7;23(33):6128-6136. doi: 10.3748/wjg.v23.i33.6128.

34.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
35.

Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver.

Su YK, Mackey RV, Riaz A, Gates VL, Benson AB 3rd, Miller FH, Yaghmai V, Gabr A, Salem R, Lewandowski RJ.

J Vasc Interv Radiol. 2017 Nov;28(11):1520-1526. doi: 10.1016/j.jvir.2017.05.011. Epub 2017 Jun 30.

PMID:
28673658
36.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C.

JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.

37.

Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.

Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB.

J Med Econ. 2017 Sep;20(9):945-951. doi: 10.1080/13696998.2017.1337019. Epub 2017 Jun 19.

PMID:
28562131
38.

Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer.

McCleary NJ, Benson AB 3rd, Dienstmann R.

Am Soc Clin Oncol Educ Book. 2017;37:232-245. doi: 10.14694/EDBK_175660. Review.

39.

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S.

J Natl Compr Canc Netw. 2017 May;15(5):563-573.

40.

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D.

J Natl Compr Canc Netw. 2017 Mar;15(3):370-398.

PMID:
28275037
41.

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma.

Hecht JR, Benson AB 3rd, Vyushkov D, Yang Y, Bendell J, Verma U.

Oncologist. 2017 Mar;22(3):243-e23. doi: 10.1634/theoncologist.2016-0479. Epub 2017 Feb 28.

42.

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma.

Benson AB 3rd, Wainberg ZA, Hecht JR, Vyushkov D, Dong H, Bendell J, Kudrik F.

Oncologist. 2017 Mar;22(3):241-e15. doi: 10.1634/theoncologist.2017-0024. Epub 2017 Feb 28.

43.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.

Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA.

J Clin Oncol. 2017 Feb;35(4):446-464. doi: 10.1200/JCO.2016.69.4836. Epub 2016 Nov 14.

PMID:
28129524
44.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA.

Am J Clin Pathol. 2016 Dec;146(6):647-669. doi: 10.1093/ajcp/aqw206. Epub 2016 Nov 14. Review.

45.

Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Garg MK, Zhao F, Sparano JA, Palefsky J, Whittington R, Mitchell EP, Mulcahy MF, Armstrong KI, Nabbout NH, Kalnicki S, El-Rayes BF, Onitilo AA, Moriarty DJ, Fitzgerald TJ, Benson AB 3rd.

J Clin Oncol. 2017 Mar;35(7):718-726. doi: 10.1200/JCO.2016.69.1667. Epub 2017 Jan 9.

46.

Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy.

Abdel-Misih SR, Wei L, Benson AB 3rd, Cohen S, Lai L, Skibber J, Wilkinson N, Weiser M, Schrag D, Bekaii-Saab T.

J Natl Compr Canc Netw. 2016 Dec;14(12):1528-1534.

47.

Epidemiology of Anal Canal Cancer.

Nelson VM, Benson AB 3rd.

Surg Oncol Clin N Am. 2017 Jan;26(1):9-15. doi: 10.1016/j.soc.2016.07.001. Review.

PMID:
27889039
48.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA.

Arch Pathol Lab Med. 2016 Dec;140(12):1345-1363. Epub 2016 Nov 14.

PMID:
27841667
49.

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.

Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ.

Gastroenterology. 2016 Dec;151(6):1155-1163.e2. doi: 10.1053/j.gastro.2016.08.029. Epub 2016 Aug 27.

50.

Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.

Farrell JJ, Moughan J, Wong JL, Regine WF, Schaefer P, Benson AB 3rd, Macdonald JS, Liu X, Yen Y, Lai R, Zheng Z, Bepler G, Guha C, Elsaleh H.

Pancreas. 2016 Nov;45(10):1485-1493.

Supplemental Content

Loading ...
Support Center